After the double-digit share price jump from the previous day, Bayer will continue to be in the focus of investors on Wednesday.
After the positive news from the USA on the subject of glyphosate, a reassessment story is emerging. Via That was also the highest price since the beginning of 2024. Over the course of time, however, the gains are reduced somewhat – most recently they rose slightly by 0.13 percent to 34.20 euros.
As part of its pharmaceutical industry outlook for 2026, Morgan Stanley now made a “tactical valuation recommendation” as a result of the news and set a price target of 40 euros. On top of that, the situation is fundamentally improving. Exane BNP Paribas increased the price target to 39 euros.
The day before, the stock market had celebrated that the US Attorney General, the so-called “Solicitor General”, had spoken out in favor of the Supreme Court, the highest US court, accepting a glyphosate ruling against Bayer for review. Bayer is hoping for a fundamental ruling.
/ag/pcs
———————-
dpa-AFX Broker – the trader news from dpa-AFX
———————-
FRANKFURT (dpa-AFX Broker)
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising